What is the antibody found in Graves’ disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

The Antibody Found in Graves' Disease

The primary antibody found in Graves' disease is thyroid-stimulating immunoglobulin (TSI), which is a type of TSH receptor antibody (TRAb) that stimulates the thyroid gland by binding to the TSH receptor. 1, 2

Types of TSH Receptor Antibodies in Graves' Disease

  • Thyroid-stimulating immunoglobulin (TSI): The primary pathogenic antibody that mimics TSH action by binding to and activating the TSH receptor, causing hyperthyroidism
  • TSH-binding inhibitor immunoglobulin (TBII): Another type of TRAb that can be measured in Graves' disease

Both TSI and TBII are collectively referred to as TSH receptor antibodies (TRAb) and are present in the vast majority of patients with Graves' disease. Studies have shown that approximately 92% of untreated Graves' patients have both positive TSI and TBII, and virtually all Graves' patients (100%) have at least one type of TRAb (either TSI or TBII) 2.

Clinical Significance of TRAb Testing

TRAb testing has important clinical applications:

  • Diagnostic value: TRAb tests have >95% sensitivity and specificity for diagnosing Graves' disease 3
  • Monitoring treatment response: TRAb levels typically decrease during successful antithyroid drug therapy 4
  • Predicting relapse: TRAb levels can predict the likelihood of remission or relapse after treatment
    • TRAb >12 IU/L at diagnosis is associated with 60% risk of relapse at 2 years and 84% at 4 years 3
    • Smooth decreases in TRAb during treatment predict higher remission rates 4

When to Test for TRAb

Guidelines recommend considering TRAb testing in the following scenarios:

  • When clinical features suggest Graves' disease, particularly with ophthalmopathy 5
  • To differentiate Graves' disease from other causes of hyperthyroidism
  • To monitor disease activity and treatment response
  • In pregnant women with current or previous Graves' disease (TRAb ≥5 IU/L indicates increased risk of fetal/neonatal thyrotoxicosis) 3

Cautions in TRAb Interpretation

  • Mildly elevated TRAb may occasionally be present in patients with transient thyrotoxicosis not due to Graves' disease 6
  • TRAb levels increase for about a year following radioactive iodine therapy before gradually declining 3
  • The pattern of TRAb changes during treatment varies between patients and can help predict outcomes 4

Other Thyroid Antibodies in Graves' Disease

While TRAb is the pathogenic antibody in Graves' disease, other thyroid autoantibodies may also be present:

  • Anti-thyroglobulin antibody (AbTG)
  • Anti-thyroid peroxidase antibody (AbTPO)
  • Anti-thyroid microsomal antibody (ATMA)

These antibodies are more commonly associated with Hashimoto's thyroiditis but can also be found in Graves' disease patients 5.

By understanding the role of TSI/TRAb in Graves' disease, clinicians can make more informed decisions about diagnosis, treatment selection, and monitoring of patients with this autoimmune thyroid disorder.

References

Research

Thyroid-stimulating immunoglobulins.

Hormone research, 1982

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.